Novocure will release data from a pivotal lung cancer trial early next year

 

• Novocure's Optune is already FDA-approved for glioblastoma and mesothelioma.
• Optune uses specially tuned frequencies to disrupt cancer cell division, improving outcomes.
• Phase 3 trial data is expected in stage IV non-small cell lung cancer in January.

https://smarts.thestreet.com/all-smarts/buying-novocure-now-could-pay-off